Prognostic factors and assessment of postoperative chemoradiotherapy in gastric cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter F. Mghirbi
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors F. Mghirbi1, M. Ayadi1, K. El Behi1, F. Letaief-ksontini2, O. Jmour1, K. Meddeb3, A. Mokrani3, Y. Yahyaoui3, H. Rais1, N. Chraiet1, A. Mezlini2
  • 1Department of Medical Oncology, Salah Azaiz Institute, Tunis, Tunisia, /
  • 2Institut Salah Azaiz, Tunis, Tunisia, /
  • 3Salah Azaiz Institute, Tunis, Tunisia, /


Gastric cancer is among the leading causes of cancer death worldwide. The mortality remains high because of a recurrence's significant number after complete surgical resection. Several postoperative therapies have been studied to decrease the risk for relapse and improve survival and there has been no standard of care yet. The primary objective of this study was to identify the relevant prognostic factors and to analyse the outcomes of adjuvant chemoradiotherapy.